1. Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells Aitziber Buqué, Jangi Sh Muhialdin, Alberto Muñoz, Begoña Calvo, Sergio Carrera, Unai Aresti, Aintzane Sancho, Itziar Rubio, Guillermo López-Vivanco Mol Cancer. 2012 APMID: 22537194
2. Thymidylate synthase expression determines Pemetrexed targets and resistance development in tumour cells. Aitziber Buqué, Unai Aresti, Begoña Calvo, Jangi Sh. Muhialdin, Alberto Muñoz, Sergio Carrera, Eider Azkona, Itziar Rubio, Guillermo L. Vivanco. PLoS One. 2013 May PMID: 236754814
3. EGFR tyrosine kinase inhibitors treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Sergio Carrera, Aitziber Buque, Eider Azkona, Unai Aresti, Begoña Calvo, Aintzane Sancho, Mikel Arruti, Maitane Nuño, Itziar Rubio, Abigail Ruiz De Lobera, Cristina López Escola, Guillermo López Vivanco. Clinical and Translational Oncology PMID: 243073954
4. Estrogen Receptor alpha Gene Expression and its Combination with Estrogen Receptor beta or Aromatase Expression Predicts Survival in Non-Small Cell Lung Cancer Unai Aresti, Sergio Carrera, Eluska Iruarrizaga, Natalia Fuente, Ines Marrodan, Abigail Ruiz de Lobera, Alberto Muñoz, Aitziber Buque, Elizabeth Condori, Irene Ugalde, Begoña Calvo and Guillermo López Vivanco PLoS One. 2014 Oct PMID: 253102214
5. Classification of current anticancer immunotherapies. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, et al. Oncotarget. 2014 Dec PMID: 255375194
6. Consensus guidelines for the detection of immunogenic cell death. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, et al. Oncoimmunology. 2014 Dec PMID: 259416214
7. Trial Watch: Peptide-based anticancer vaccines Jonathan Pol*, Norma Bloy*, Aitziber Buqué*, Alexander Eggermont, Isabelle Cremer, Catherine SautèsFridman, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer and Lorenzo Galluzzi Oncoimmunology, 2015 PMID: 261374054
8. Trial Watch. Immunomodulatory monoclonal antibodies for oncological indications Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W.H., Fučíková, J., Galon, J., Marabelle, A., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G. and L. Galluzzi.. Oncoimmunology, 2015 PMID: 261374034
9. Trial Watch: Naked and vectored DNA-based anticancer vaccines Aitziber Buqué*, Norma Bloy*, Fernando Aranda*, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Catherine SautèsFridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer† and Lorenzo Galluzzi† Oncoimmunology. April 2015 PMID: 261554084
10. eIF2α phosphorylation as a biomarker of immunogenic cell death. Kepp O, Semeraro M, Bravo-San Pedro JM, Bloy N, Buqué A, Huang X, Zhou H, Senovilla L, Kroemer G, Galluzzi L. Semin Cancer Biol. 2015 Mar. PMID: 257491944
11. Trial Watch. Adoptive cell transfer for oncological indications. Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W.H., Fučíková, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G. and L. Galluzzi. Oncoimmunology, 2015 PMID: 264513194
12. Podocalyxin-like protein 1 regulates anti-tumor immune response in breast cancer cells Laura CV: Aitziber Buque Martinez, PhD 3 Amo1 , Estíbaliz Tamayo-Orbegozo1 , Natalia Maruri1 , Aitziber Buque2#, Miren Solaun1 , Marta Riñón1 , Arantza Arrieta1 , Susana Larrucea1* Cancer Lett. 2015 Aug PMID: 262767144
13. Trial Watch: Adoptive cell transfer for oncological indications. Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Oncoimmunology. 2015 Nov PMID: 264513194
14. Morphometric analysis of immunoselection against hyperploid cancer cells. Bloy N, Sauvat A, Chaba K, Buqué A, Humeau J, Bravo-San Pedro JM, Bui J, Kepp O, Kroemer G, Senovilla L. Oncotarget. 2015 Dec PMID: 265176774
15. Immunological effects of conventional chemotherapy and targeted anticancer agents Lorenzo Galluzzi, Aitziber Buqué, Oliver Kepp, Laurence Zitvogel † and Guido Kroemer † Cancer Cell 2015 Dec. PMID: 266783374
16. Trial Watch - Immunostimulation with cytokines in cancer therapy Erika Vacchelli*, Fernando Aranda*, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Laurence Zitvoge, Guido Kroemer †, and Lorenzo Galluzzi † OncoImmunology 2016 Feb PMID: 270574684
17. Trial Watch - Oncolytic viruses and cancer therapy Aitziber Buqué*, Jonathan Pol*, Fernando Aranda, Norma Bloy, Isabelle Cremer, Alexander Eggermont, Philippe Erbs; Jitka Fucikova, Jérôme Galon, JeanMarc Limacher; Xavier Preville; Radek Spisek, Laurence Zitvoge, Guido Kroemer † and Lorenzo Galluzzi † Oncoimmunology. 2016 Feb. PMID: 270574694
18. Trial Watch - Immunostimulation with Toll-like receptor agonists in cancer therapy Kristina Iribarren, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi OncoImmunology 2016 Mar. PMID: 271413454
19. Trial Watch - Small molecules targeting the immunological tumor microenvironment for cancer therapy Aitziber Buqué, Norma Bloy, Fernando Aranda, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi Oncoimmunology. 2016 Mar PMID: 274716174
20. Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer Baracco EE, Pietrocola F, Buqué A, Bloy N, Senovilla L, Zitvogel L, Vacchelli E, Kroemer G. Oncoimmunology. 2016 Jun PMID: 274716104
21. Prevention of breast cancer by RANKL/RANK blockade. Galluzzi L, Buqué A, Kroemer G. Cell Res. 2016 Jul. PMID: 273252974
22. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, Senovilla L, Marino G, Aranda F, Durand S, Sica V, Chery A, Lachkar S, Sigl V, Bloy N, Buque A, Falzoni S, Ryffel B, Apetoh L, Di Virgilio F, Madeo F, Maiuri MC, Zitvogel L, Levine B, Penninger JM, Kroemer G. Cancer Cell. 2016 Jul PMID: 274115894
23. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Oncoimmunology. 2016 Mar PMID: 274716174
24. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Oncoimmunology. 2016 Jul PMID: 27757313 CV: Aitziber Buque Martinez, PhD 44
25. The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy N, Humeau J, Buque A, Kepp O, Zitvogel L, André F, Mathieu MC, Delaloge S, Kroemer G. Oncoimmunology. 2016 Aug PMID: 278536394
26. Immunogenic cell death in cancer and infectious disease. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Nat Rev Immunol. 2017 Feb PMID: 277483974
27. Reply: The complement system is also important in immunogenic cell death. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Nat Rev Immunol. 2017 Feb PMID: 280283124
28. Reply: Immunosuppressive cell death in cancer. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Nat Rev Immunol. 2017 May PMID: 284808964
29. Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, Drijfhout JW, Meurice G, Walter S, Fritsche J, Weinschenk T, Rammensee HG, Melief C, Thibault P, Perreault C, Pol J, Zitvogel L, Senovilla L, Kroemer G Immunol Rev. 2017 Nov PMID: 290272304
30. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Oncoimmulogy. 2018 Feb PMID: 298725694
31. Modeling Tumor Immunology and Immunotherapy in Mice. Buqué A, Galluzzi L Trends Cancer. 2018 Sep PMID: 301498764
32. Anticancer effects of anti-CD47 immunotherapy in vivo. Kristina Iribarren*, Aitziber Buque*, Laura Mondragon, Wei Xie, Sarah Levesque, Jonathan Pol, Laurence Zitvogel, Oliver Kepp** and Guido Kroemer** Oncoimmunology. 2018 Dec PMID: 307235824
33. Monitoring abscopal responses to radiation in mice Maria Esperanza Rodriguez-Ruiz, Takahiro Yamazaki, Aitziber Buqué, Norma Bloy, Viviane A. O. Silva, Lena Stafford, Ai Sato and Lorenzo Galluzzi. Methods in Enzymology 2019 April PMID: 321225404
34. Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients Maria Esperanza Rodriguez-Ruiz*, Aitziber Buqué*, Michal Hensler, Jonathan Chen, Norma Bloy, Giulia Petroni, Ai Sato, Takahiro Yamazaki, Jitka Fucikova and Lorenzo Galluzzi Oncoimmunology. 2019 Aug PMID: 316461054
35. Apoptotic caspases cut down the immunogenicity of radiation Aitziber Buqué* , Maria E. RodriguezRuiz* , Jitka Fucikovac and Lorenzo Galluzzi. Oncoimmunology. 2019 Aug PMID: 316461034
36. Today's Special on the Anticancer Menu: Immunomodulation by Antifolates. Buque A, Galluzzi L, Casares N. Clin Cancer Res. 2019 Dec PMID: 315622054
37. Methods to Detect Immunogenic Cell Death In Vivo. Yamazaki T, Buqué A, Rybstein M, Chen J, Sato A, Galluzzi L. Methods Mol Biol. 2020 PMID: 315021644
38. Synergistic Effect of Hypofractionated Radiation and PD-1 Blockage in an Endogenous Model of HR+ Breast Cancer. A.Buqué, T.Tamazaki, L.Galluzzi, S.C.Formenti International Journal of Radiation Oncology*Biology*Physics 2019 Sept 1 CV: Aitziber Buque Martinez, PhD 54
39. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Takahiro Yamazaki, Aitziber Buqué, Tyler D. Ames and Lorenzo Galluzzi Oncoimmunology 2020 Feb PMID: 321175854
40. Possible mechanisms of cancer prevention by nicotinamide Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.xBuqué A, Bloy N, Kroemer G, Galluzzi L. Br J Pharmacol. 2020 May PMID: 323832274
41.Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Aitziber Buqué, Norma Bloy, Maria Perez-Lanzón, Kristina Iribarren, Juliette Humeau, Jonathan G. Pol, Sarah Levesque, Laura Mondragon, Takahiro Yamazaki, Ai Sato, Fernando Aranda, Sylvère Durand, Alexandre Boissonnas, David Enot, Margerie Kremer, Gautier Stoll, Yang Hu, Olivier Elemento, Fabrice André, Laurence Zitvogel, Suzette Delaloge, Guido Kroemer ** and Lorenzo Galluzzi** Nat Commun. 2020 Jul PMID: 327328754
42. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Yamazaki T, Kirchmair A, Sato A, Buqué A, Rybstein M, Petroni G, Bloy N, Finotello F, Stafford L, Navarro Manzano E, Ayala de la Peña F, García-Martínez E, Formenti SC, Trajanoski Z, Galluzzi L. Nat Immunol. 2020 Aug PMID: 327478194
43. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Nat Rev Clin Oncol. 2020 Aug. PMID: 327600144
44. NK cells beat T cells at early breast cancer control. Buque A, Bloy N, Petroni G, Kroemer G, Galluzzi L. Oncoimmunology. 2020 Aug PMID: 329231694
45. Immunomodulation by targeted anticancer agents. Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer and Lorenzo Galluzzi. Cancer Cell. 2021 Mar. PMID: 333384264
46. Radiotherapy delivered before CDK4/6 inhibitors mediates superior therapeutic effects in ER+ breast cancer Giulia Petroni, Aitziber Buqué, Takahiro Yamazaki, Norma Bloy, Maurizio Di Liberto, Selina Chen-Kiang, Silvia C. Formenti, and Lorenzo Galluzzi Clin Cancer Res. 2021 Jan PMID: 334953114
47. Ketosis versus carbotoxicity - metabolism determines the outcome of cancer immunotherapy. Buqué A, Galluzzi L, Kroemer G Mol Cell Oncol. 2021 Jan. PMID: 335536144
48. MPA/DMBA-driven mammary carcinomas. Buqué A, Perez-Lanzón M, Petroni G, Humeau J, Bloy N, Yamazaki T, Sato A, Kroemer G, Galluzzi L. Methods Cell Biol. 2021 PMID: 337851594
49. Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells. Sato A, Buque A, Yamazaki T, Bloy N, Petroni G, Galluzzi L. STAR Protoc. 2021 May PMID: 340415024
50. Targeting serine in cancer: Is two better than one? Aitziber Buqué, Lorenzo Galluzzi* and David C. Montrose* Trends in Cancer 2021 Jun. PMID: 342190534
51. Targeting oncogene and non-oncogene addiction to inflame the tumor microenvironment. Giulia Petroni*, Aitziber Buqué*, Lisa M. Coussens and Lorenzo Galluzzi Nat Rev Drug Discov. 2022 PMID: 352927714
52. Emergent impact of lifestyle on tumor progression and response to therapy. Buqué, A. and L. CV: Aitziber Buque Martinez, PhD 6 Galluzzi. Int Rev Mol Cell Biol, 2022. In press4
53. Nicotinamide drives T cell activation in the mammary tumor microenvironment. Yang Hu, Norma Bloy, Olivier Elemento and Aitziber Buqué. J Transl Med 2022 PMID: 356593144
54. PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes. Cristina C. Clement, Jaspreet Osan, Aitziber Buque, Padma Nanaware, Yoke-Chen Chang, Giorgio Perino, Madhur Shetty, Takahiro Yamazaki, Wanxia Li Tsai, Aleksandra M. Urbanska J. Mauricio Calvo-Calle, Shakti Ramsamooj, Diego Vergani, Giorgina Mieli-Vergani, Benedetta Terziroli, Beretta-Piccoli, Massimo Gadina, Cristina Montagna, Marcus DaSilva Goncalves, Federica Sallusto, Lorenzo Galluzzi, Rajesh K. Soni, Lawrence J. Stern, Laura Santambrogio Science Immunology 2022 PMID: 359848924
55. Quantification of cytosolic DNA species by immunofluorescence microscopy and automated image analysis Ai Sato, Norma Bloy, Claudia Galassi, Carlos Jiménez-Cortegana, Vanessa Klapp, Artur Aretz, Emma Guilbaud, Takahiro Yamazaki, Giulia Petroni, Lorenzo Galluzzi*, Aitziber Buqué* Methods Cell Biol. 2022 PMID: 360642194
56. RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells. Galassi C, Ruan Y, Sato A, Jiménez-Cortegana C, Klapp V, Bloy N, Guilbaud E, Petroni G, Buqué A, Galluzzi L, Yamazaki T. Methods Cell Biol. 2022 PMID: 360642214
57. Cytofluorometric assessment of acute cell death responses driven by radiation therapy. ÁlvarezAbril B, Bloy N, Galassi C, Sato A, Jiménez-Cortegana C, Klapp V, Aretz A, Guilbaud E, Buqué A, Galluzzi L, Yamazaki T. Methods Cell Biol. 2022 PMID: 360642234
58. Emergent impact of lifestyle on tumor progression and response to therapy. Buqué A, Montrose DC, Galluzzi L. Int Rev Cell Mol Biol. 2022 PMID: 362837694
59. Quantitative assessment of mitophagy in irradiated cancer cells. Guilbaud E, Spada S, Bloy N, Galassi C, Sato A, Jiménez-Cortegana C, Aretz A, Buqué A, Yamazaki T, Demaria S, Galluzzi L. Methods Cell Biol. 2023 PMID: 367100544
60. Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors. Klapp V, Buqué A, Bloy N, Sato A, Yamazaki T, Zhou XK, Formenti SC, Galluzzi L, Petroni G. J Transl Med. 2023 PMID: 4
Patient comments